Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer

 

Marie-Emmanuelle Legrier1, Ivan Bièche2, Julie Gaston1, Arnaud Beurdeley1, Vanessa Yvonnet1, Olivier Déas1,
Aurélie Thuleau3, Sophie Château-Joubert4, Jean-Luc Servely4,5, Sophie Vacher2, Myriam Lassalle1,
Stéphane Depil6, Gordon C Tucker6, Jean-Jacques Fontaine4, Marie-France Poupon1, Sergio Roman-Roman3,
Jean-Gabriel Judde1, Didier Decaudin3,7, Stefano Cairo*,1,8,9 and Elisabetta Marangoni*,3,9

 

1 XenTech, 4 rue Pierre Fontaine, Evry 91000, France; 2 Genetics Department, Hospital, Institut Curie, 26 rue d’Ulm, Paris 75005, France; 3 Translational Research Department, Institut Curie, 26 rue d’Ulm, Paris 75005, France; 4 Department of Pathology, Veterinary School of Alfort, Maisons-Alfort 94704, France; 5 INRA, Phase Department, Nouzilly, France; 6Institut de Recherches Servier, PIT Oncology, Croissy-sur-Seine 78290, France; 7 Medical Oncology Department, Institut Curie, 26 rue d’Ulm, Paris 75005, France and 8 University of Ferrara, LTTA Centre, Department of Morphology, Surgery and Experimental Medicine, Ferrara, Italy

British Journal of Cancer (2015), 1–11 | doi: 10.1038/bjc.2015.398

bt-news